Novartis Patent Suit Over Generic MS Drug Won't Be Trimmed
A Delaware federal judge rebuffed a generic-drug maker's call to let its subsidiaries out of Novartis' patent suit over multiple sclerosis drug Gilenya, ruling Tuesday that the generic company's units each...To view the full article, register now.
Already a subscriber? Click here to view full article